The ADRIFT (Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Treated with Left Atrial Appendage Closure) study, presented Monday at the European Society of Cardiology Congress 2019 by Gilles Montalescot, MD, PhD, demonstrated that a reduced dose of rivaroxaban alone is superior to dual-antiplatelet therapy in controlling thrombin generation (coagulable state).